PRF Technologies FY26 H1 net loss widens to $2.8 million

• PRF Technologies posted a net loss attributable to shareholders of $2.8 million for the six months ended June 30, 2026, widening from $2.3 million.
• R&D expenses rose to $0.8 million from $0.3 million, due to expanded Solar activity and increased LayerBio clinical development.
• G&A costs fell 39% to $1.2 million on lower consulting, legal and share-based compensation expenses.
• Cash, cash equivalents, short-term deposits and restricted cash climbed to $11.6 million at June 30, up from $4.2 million at year-end 2025.
• FDA cleared the IND for OcuRing-K ahead of a U.S. Phase II cataract surgery trial, with enrollment expected in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PRF Technologies Ltd. published the original content used to generate this news brief on September 03, 2026, and is solely responsible for the information contained therein.